姓名：宋洋洋

导师情况：博士生导师

研究领域：RNA表观遗传，干细胞遗传发育 

Email: y_song@tongji.edu.cn

通讯地址：上海市杨浦区四平路1239号，同济大学生命科学与技术学院，邮编200092

个人简介：

博士毕业于香港大学医学院，随后加入新加坡国立大学任高级研究科学家，2024年起任同济大学“青年百人计划”研究员，博士生导师，兼任同济大学附属普陀人民医院研究员，入选上海市海外高层次人才计划引进人才。获美国癌症协会年会杰出临床学者奖、香港特别行政区政府外展体验奖、香港大学医学院杰出贡献奖等多个奖项和荣誉。 

研究领域围绕肿瘤干细胞和干细胞遗传发育，揭示肿瘤发病机制中RNA表观遗传学的复杂性以及探索 RNA 靶向疗法。主要包括RNA editing、alternative splicing、circRNA等RNA修饰的特异性转录组多样性中的作用，并结合人工智能技术开发了RNA编辑、可变剪接等RNA靶点的小核酸药物（ASO、siRNA）和小分子药物。近年来以第一作者或通讯作者（含共同）在Journal of Hepatology、Gastroenterology、Proceedings of the National Academy of Sciences、Nucleic Acids Research等杂志发表多篇学术论文。多次在RNA协会年会、新加坡国立大学癌症研究所年会、美国癌症协会年会进行学术报告及获奖。

 研究方向：

1. RNA编辑干预在肝癌与结直肠癌肿瘤异质性和治疗机制中的作用

2. RNA腺苷脱氨酶（ADAR）在发育、免疫调控与肿瘤发生中的平衡机制研究

3. 基于结构-功能-筛选一体化平台的RNA调控机制解析与精准干预

本课题组常年招聘博士后及科研助理，也欢迎博士生、硕士生和本科生报考和实习。

代表性论文：

1. Han J*, Song Y*, Xie J, Shen H, Gan WL, Ng L, Ng BYL, Ng VHE, Sui X, Tano V, Tang SJ, Chen L. Modulation of m6A RNA modification by DAP3 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2024 Oct;121(40):e2404509121. *Co-first author. 

2. Song Y, An O, Ren X, Chan TH, Tay DJ, Tang SJ, Han J, Hong HQ, Ng VHE, Ke X, Shen H, Pitcheshwar P, Lin SJ, Leong KW, Molias FB, Yang H, Kappei D, Chen L. RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis. Journal of Hepatology. 2021 Jan; 74(1):135-147.

3. Song Y#,*, Ke X*, Chen L#. Potential use of RNA-based therapeutics for breast cancer treatment. Current Medicinal Chemistry 2021;28(25):5110-5136. *Co-first author, # Co-corresponding author. 

4. Qi L*, Song Y*, Chan TH, Lin CH, Yang H, Hong HQ, Tay DJT, Lin JS, Maury JJP, Tenen DG, Chen L, An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer. Nucleic Acids Research. 2017 Oct 13;45(18):10436-10451. *Co-first author.

5. Song Y, Chen L, Zeng T, Chan TH, Lian QZ, Chow R, Cai X, Li Y, Li Y, Liu M, Wong N, Yuan YF, Pei D, Guan XY. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Gastroenterology, 2015 Oct;149(4):1068-81.e5.

6. Gan WL, Ren X, Ng VHE, Song Y, Tano V, Han J, Ng L, An O, Xie J, BLY, Tay DJT, Tang SJ, Shen H, Khare S, Young DY, DasGupta R, Chen L. Hepatocyte-macrophage crosstalk via the PGRN-EGFR axis modulates ADAR1-mediated immunity in the liver. Cell Reports. 2024 Jul 23;43(7):114400. 

7. Guo J, Chen S, Onishi Y, Shi Q, Song Y, Mei H, Chen L, Kool ET, Zhu RY. RNA Control via Redox-Responsive Acylation. Angew Chem Int Ed Engl. 2024 May 21;63(21):e202402178.

8. Guo M, Chan HMT, Zhou QL, An O, Li Y, Song Y, Tan ZH, Ng HEV, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, Ooi MG, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, Koh BTH, Chan MC, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG. Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis. Blood. 2023 Jun 22;141(25):3078-3090.

9. Han J, An O, Ren X, Song Y, Tang SJ, Shen H,  Ke XY, Ng VHE, Tay DJ, Tan HQ, Kappei D, Yang H, Chen L. Multilayered Control of Splicing Regulatory Networks by DAP3 Leads to Widespread Alternative Splicing Changes in Cancer. Nature Communications. 2022 Apr 4;13(1):1793.

10. Shen H, An O n, Ren X, Song Y, Tang SJ, Ke XY, Han J, Tay DJ, Ng VHE, Molias FB, Pitcheshwar P, Leong KW, Tan KK, Yang H, Chen L. ADARs act as potent regulators of circular transcriptome in cancer. Nature Communications. 2022 Mar 21;13(1):1508.

11. Molias FB, Sim A, Leong KW, An O, Song Y, Ng VHE, Lim MWJ, Ying C, Teo JXJ, Göke J, Chen L. Antisense RNAs influence promoter usage of their counterpart sense genes in cancer. Cancer Research. 2021 Dec 1;81(23):5849-5861.

12. Tay DJ, Song Y, Peng B, Toh TB, Hooi L, Kaixin Toh DF, Hong H, Tang SJ, Han J, Gan WL, Man Chan TH, Krishna MS, Patil KM, Maraswami M, Loh TP, Dan YY, Zhou L, Bonney GK, Kah-Hoe Chow P, Chen G, Kai-Hua Chow E, Le MT, Chen L. Targeting RNA Editing of Antizyme Inhibitor 1: a Potential Oligonucleotide-Based Antisense Therapy for Cancer. Molecular Therapy. 2021 Nov 3;29(11):3258-3273.

13. An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha SY, Lee MH, Tay ST, Ong X, Keng ATL, Ng M, Tantoso E, Chen L, Tan P, and Yong WP. 3G Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Cancer Research. 2021 May 15;81(10):2788-2798.

14. Han J, An O, Hong H, Chan TH, Song Y, Shen H, Tang SJ, Lin JS, Ng VHE, Tay DJ, Molias FB, Pitcheshwar P, Yang H, Chen L. Suppression of Adenosine-to-Inosine (A-to-I) RNA Editome by Death Associated Protein 3 (DAP3) Promotes Cancer Progression. Science Advances, 2020 Jun 17;6(25):eaba5136.

15. Tang SJ, Shen H, An O, Hong HQ, Li J, Song Y, Han J, Tay DJ, Ng VHE, Molias FB, Leong KW, Pitcheshwar P, Yang H, Chen L. Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. Nature Communications. 2020 Feb 7;11(1):799.

16. Hong HQ, An O, Chan TH, Ng VHE, Kwok HS, Lin JS, Qi L, Han J, Tay DJT, SJ, Yang H, Song Y, Molias FB, Tenen DG and Chen L. Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer. Nucleic Acids Research, 2018 Sep 6;46(15):7953-7969.

17. Chan TH, Qamra A, Tan KT, Guo J, Yang H, Qi L, Lin JS, Ng VH, Song Y, Hong H, Tay ST, Liu Y, Lee J, Rha SY, Feng Z, So JB, Bin Tean T, Guan YK, Rozen S, Tenen DG, Tan P, Chen L. ADAR-mediated RNA editing predicts progression and prognosis of Gastric Cancer. Gastroenterology. 2016 Oct;151(4):637-650.e10.

18. Liu M, Chen L, Ma N, Chow R, Li Y, Song Y, Chan THM, Fang S, Yang X, Xi S, Jiang L, Li Y, Zeng T, Li Y, Yuan Y, and Guan XY., CHD1L Promotes Lineage Reversion of Hepatocellular Carcinoma through Opening Chromatin for Key Developmental Transcription Factors. Hepatology 2016 May;63(5):1544-59.

19. Chow RK, Sin ST, Liu M, Li Y, Chan TH, Song Y, Chen L, Kwong DL, Guan XY. AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-kB signaling pathways. Oncotarget. 2016 Oct 18;8(48):83469-83479 

20. Liu M, Li Y, Chen L, Chan TH, Song Y, Fu L, Zeng T, Dai YD, Zhu YH, Li Y, Chen J, Yuan YF, Guan XY. Allele-specific imbalance of Oxidative Stress Induced Growth Inhibitor 1 contributes to the progression of hepatocellular carcinoma. Gastroenterology, 2014 Apri146(4):1084-96.

21. Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut.2013 May;63(5):832-43.

22. Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nature Medicine. 2013 Feb;19(2):209-16.

23.  Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X, Zhao Z, Kong KL, Dong S, Song Y, Chan TH, Guan XY. MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene. 2012 May 3;31(18):2298-308. 

专利：

1. 关新元, 宋洋洋, 李炎. 中国发明专利：抑癌基因ATOH8及其编码基因的应用, 专利号: CN2014103736103A. 申请时间2013年12月27日，授权时间2016年2月17日

2. 关新元, 宋洋洋, 李炎. 中国发明专利：抑癌基因ATOH8及其编码基因在制备iPSC中的应用, 专利号: CN105420195A. 申请时间2013年12月27日，授权时间2019年5月21日